Overcoming chemoresistance in non-small cell lung cancer: Insights into the influence of inflammatory factors on treatment response

Figure 4 Inhibition of interleukin-6 reduces cell viability and induces apoptosis in drug-resistant non-small cell lung cancer cells under cisplatin treatment. A: Cell counting kit-8 was adopted to assess the viability and half-maximal inhibitory concentration of cells in each group under cisplatin (DDP) treatments; B: Cells in each group were treated with DDP (20 μmol/L), and flow cytometry was used to determine the apoptotic rate; C: Representative flow cytometry plots and quantification of apoptotic rates in A549 and A549/DDP cells treated with DDP (20 μmol/L) ± tocilizumab (TCZ); D: Representative flow cytometry plots and quantification of apoptotic rates in SK-MES-1 and SK-MES-1/DDP cells treated with DDP (20 μmol/L) ± TCZ. Data were presented as mean ± SD (n = 3). ^aP < 0.05, ^bP < 0.01 vs A549 or SK-MES-1; ^cP < 0.05 vs A549/DDP or SK-MES-1/DDP. Statistical significance was determined using one-way ANOVA followed by Tukey’s post hoc test. DDP: Cisplatin; TCZ: Tocilizumab.